symbol not found



symbol not found



symbol not found



symbol not found



symbol not found



symbol not found



symbol not found



symbol not found

Recent Articles from TheStreet

After Red-hot IPO, Chinese Biotech Firm Kintor Eyes Blockbuster Drugs For Prostate Cancer, Sex Hormone-related Hair Loss

Atea Pharma Stock Plunges After COVID Treatment Trial Disappoints; Merck Jumps

Atea Pharmaceuticals could shed more than $2 billion in value Tuesday after the drugmaker said a mid-stage trial of its developing COVID treatment failed to meet expectations.

What to know about Cloudflare's Upcoming IPO

Investing in the Cloud: Consider Cloudflare and Digital Ocean

Cloud-software growth stocks have been a bright spot in an uncertain market. Investors might look closely at Cloudflare and Digital Ocean.

Philip Morris International Lead

Philip Morris Ekes Out Third-Quarter Earnings Beat

Philip Morris posts a third-quarter earnings beat as sales of its smokeless non-tobacco products continue strong, though cautions on supply chain impact.

The Travelers Companies Lead

Travelers Posts Third Quarter Earnings Beat on Record Net Written Premiums

Travelers Companies posts third-quarter earnings that exceed analysts’ forecasts as a drop in what it calls ‘catastrophic losses’ offsets record net written premiums.

Lufax is set to make the biggest splash on the NYSE by a Chinese company since e-commerce giant Alibaba's IPO in 2014. Photo: Reuters

Stock Market Today: Dow Gains On Earnings Strength; Housing Starts Disappoint

Solid third quarters continue to power stocks higher Tuesday, even as growth and inflation signals remain stubbornly persistent as oil prices top $85 a barrel in overnight trading.

Procter & Gamble Is Under Siege From an Activist Investor

Procter & Gamble Stock Slips After Q1 Earnings Beat; 2022 Forecast Unchanged

Procter & Gamble held its 2022 forecasts in place, seeing sales growth of between 2% and 4%, following stronger-than-expected first quarter earnings.

No More Tears for Johnson & Johnson?

Johnson & Johnson Stock Gains as Vaccine Sales Boost Q3 Earnings, 2021 Forecasts

Johnson & Johnson said it sees 2021 vaccine sales of $2.5 billion, with overall revenues rising to between $94.1 billion to $94.6 billion, following its Q3 earnings beat.

Stock Market Lead

Stocks Gain, SEC GameStop Report, Rent The Runway IPO - 5 Things You Must Know

Stocks edge higher ahead of earnings; SEC says GameStop surge powered by believers; FDA set to approve "mix & match' COVID boosters; DraftKings faces Entain bid deadline and Rent the Runway seeks $1.3 billion valuation in Nasdaq IPO.